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Whole-genome analyses of human medulloblastomas
show that the dominant clone at relapse is present as
a rare subclone at primary diagnosis.the recurrent tumor is often highly divergent from theThe extent of intratumor heterogeneity and how treat-
ment affects clonal evolution of cancer is an emerging
theme in the field of cancer biology. In the era of tar-
geted therapy, the presence of pre-existing treatment-
resistant subclones within the tumor is a critical barrier
to achieving durable responses. Targeted drugs result in
a significant clinical improvement if they are directed at
the founding clonal mutations shared by all of the
billions of cells in a tumor. However, growing evidence
indicates that tumors also contain many subclonal muta-
tions which are often present in only a few cancer cells
[1–3]. These subclones are derived from the founding
clone and are established by the additional mutations
they acquire, which are not present in the bulk of the
tumor. Importantly, many subclonal mutations cannot
be detected because their abundance falls below the de-
tection limit of standard genome or exome sequencing
techniques [1]. In the case of solid tumors, spatial het-
erogeneity and tumor sampling errors can also lead to
subclonalmutations being missed [1]. However, subclo-
nal mutations can be clinically relevant [2, 4]. For ex-
ample, in patients with chronic lymphocytic leukemia,
the presence of subclonal populations impacts prognosis
and clinical outcome [2]. Recent studies have also re-
vealed that tumor cells corresponding to the relapse
clone are often present as minor subclones within the
primary tumor before the initiation of therapy, which
suggests that genetic abnormalities contributing to
recurrence are selected for during treatment [5–8].* Correspondence: maley@asu.edu
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clonal evolution in relapsed medulloblastoma. By analyz-
ing whole-genome sequencing (WGS) of 33 pairs of
human diagnostic and post-therapy medulloblastoma
samples, the authors show that the dominant clone in
dominant clone in the primary tumor. These results
were also corroborated in a murine medulloblastoma
model. The authors concluded that the dominant clone
at recurrence arose through clonal selection of a pre-
existing minor subclone present at diagnosis (Fig. 1).
This study represents an important advance in
understanding the clonal dynamics of recurrence in
medulloblastoma.Recurrent tumors are very different from tumors
at diagnosis and should be biopsied
An important consequence of the clonal nature of can-
cers is the spatial and temporal variation in the clonal
composition within both primary and relapsed tumors,
which makes the identification of trunk mutations of a
specific tumor type a challenging problem. Morrissy and
colleagues found that in 75 % of cases, the mutations
that appeared to be clonal (“trunk mutations”) at diagno-
sis were either absent at relapse or not present in all the
neoplastic cells. Previous studies have analyzed clonal
evolution of recurrence in different cancers [2, 5, 6]. For
example, in pediatric patients with acute lymphoblastic
leukemia (ALL) it has been observed that there is a sig-
nificant increase in the average number of copy number
alterations per case in relapsed B-cell ALL compared
with the matched diagnostic sample [5]. Morrissy and
colleagues [9] performed WGS on matched diagnosis
and relapse samples from 33 pediatric cases. In 13 out of
15 patients with matched germline DNA, there was on
average a fivefold increase in the somatic mutational
burden at recurrence. Furthermore, they found that, on
average, only less than 12 % of somatic single nucleotide
variants (SNVs) and indels were present in both the
diagnostic and the relapse samples, demonstrating ale is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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Fig. 1 A timeline of neoplastic progression, therapy, and recurrence. We illustrate a hypothetical example of clonal expansion of neoplastic cells over
time (x-axis). A cell lineage accumulates somatic mutations (and other genetic and epigenetic alterations), one of which initiates carcinogenesis
(red star). These somatic mutations are shared across all neoplastic cells. During neoplastic progression, two separate lineages accumulate driver
damaging mutations (green and purple circles) that lead to transformation events. A damaging mutation is defined as a nonsynonymous mutation that
is predicted to have a functional effect. We define a transformation (black star) as the last mutational hit to make the clone malignant. During therapy
most of the lineages are eliminated. However, a rare subclone at diagnosis with a resistance mutation (orange star) survives therapy and may continue
to expand until reaching a detectable population size (recurrence). This hypothetical scenario reflects the 41.6 % of cases in which Morrissy and
colleagues [9] did not find common damaging mutations between diagnosis and recurrence samples
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mentioning that relapse samples also had an increased
proportion of transversions, presumably due to DNA
damage induced by the radiation therapy. They also cor-
roborated these findings in a mouse medulloblastoma
model, concluding that, similar to human medulloblas-
toma, there is a very small overlap (<5 %) of genetic
events that appear to be in all of the cancer cells be-
tween the matched diagnostic and recurrent tumor sam-
ples. This implies that systematic multiregion sampling
before treatment and at the time of recurrence is essen-
tial both to better understand clonal evolution and for
the development of effective targeted therapies.
Subclonal diversity makes tumors more evolvable
and robust to interventions
Recent studies have identified rare subclones within the
tumor that harbor resistance mutations before the initi-
ation of therapy [5–8], which suggests that standing
subclonal variation within a tumor may be the most
important factor for the evolution of acquired resistance
to treatment. In natural systems, it is well-studied that
populations can adapt to novel environments in two dif-
ferent ways: selection acting on pre-existing genetic vari-
ants and selection acting on new mutations. Adaptation
from standing genetic variation is likely to be faster than
from novel mutations, not just because beneficial muta-
tions are immediately available in the new environment,but also because they might start at higher frequencies.
Morrissy and colleagues [9] found that the majority
(60.5 %) of damaging (i.e., non-synonymous variants pre-
dicted to have a functional impact on the protein) clonal
mutations present in the primary tumor sample consist-
ently decreased in prevalence after therapy, and either
became subclonal (25.9 %) or disappeared completely
(34.6 %). Additionally, only 25 % of patients retained the
full set of clonal SNVs after therapy, with most cases
having no retention (41.6 %) or partial retention (33.3 %)
of damaging clonal mutations. Importantly, all relapses
shared somatic mutations with the primary tumor and
therefore shared a common origin. This indicates that in
41.6 % of cases, the tumor was initiated by nondamaging
mutations, which highlights the importance of considering
other genetic modifications (e.g., mutations on non-
coding regions, epigenetics, or copy number aberrations)
both to study tumor evolutionary dynamics and to identify
new candidate drivers. Taken together, these findings indi-
cate that the majority of relapsed tumors had a clear rela-
tionship to the medulloblastoma clone at diagnosis, either
arising through clonal evolution of the diagnostic domin-
ant population or arising from an ancestral subclone,
which was not the predominating clone at diagnosis.
Distant relatives may never leave
A common model of clonal evolution in neoplastic
progression envisions driver mutations causing clonal
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lation and reach fixation (100 % frequency), driving
other clones extinct. If such a mutation did reach
fixation, it would appear as a trunk mutation, present in
all the neoplastic cells. Morrissy and colleagues [9]
provide evidence that such clonal expansions rarely
reach fixation, and that distant relative clones remain in
the neoplasm at very low frequency, below the threshold
for detection at diagnosis. The authors performed ultra-
deep sequencing of patient-specific SNVs from 20 cases.
Sixteen out of the 20 patients had evidence of rare
subclones initially present at frequencies less than 5 %
before the initiation of treatment. The lack of evidence
of rare subclones in the remaining four patients may be
simply due to sampling and spatial heterogeneity, or
limits of detection of ultradeep sequencing itself [1].
This finding is consistent with previous studies [5–8].
For example, it has been shown that colorectal tumors
that are wild type for KRAS are often sensitive to
targeted epidermal growth factor receptor (EGFR) block-
ade; however, KRAS mutations become detectable at the
time of acquired resistance to this targeted drug. An
analysis of the evolutionary dynamics of cancer cells
with KRAS mutations in patients with colorectal cancer
after treatment demonstrated that these mutations had
been present before the initiation of EGFR blockade, in
rare subclones harboring approximately thousands of
cancer cells [6]. Additional evidence for these rare
subclones has been provided by the detection of low
levels of KRAS mutations by sensitive PCR technology
in patients with colorectal cancer who were found to be
wild type for KRAS by standard methods [1]. Therefore,
with the advent of more powerful sequencing methods
in the future, determining the presence of treatment-
resistant subclones within a tumor at the time of diagno-
sis will be crucial to decide how single therapeutic
agents could be combined in order to control or sup-
press clonal evolution.
New approaches to managing cancers
How can we deal with so much standing variation in a
tumor at diagnosis, and the resulting evolvability of the
tumor? In many cases, we may assume that a resistant
clone is already present at diagnosis. The standard re-
sponse has been to combine drugs in the hope that there
are no cancer cells present that are resistant to all the
drugs in the cocktail. While multidrug cocktails typically
extend survival longer than monotherapy, resistance still
evolves. Evolutionary theory suggests that we may slow
or even avoid the evolution of resistance by using cyto-
static drugs over cytotoxic drugs, by targeting the evol-
vability of the tumor itself by lowering the mutation rate
and extending the generation time of the cancer cells,
attempting to maintain control of the tumor by keepingsome sensitive cells alive (“adaptive therapy”), or by
selecting against the resistant clones [10]. At the very
least, we must biopsy tumors at recurrence because they
are likely to be quite different from the tumor that was
biopsied at diagnosis.
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